SRRK icon

Scholar Rock

44.78 USD
+2.69
6.39%
At close Dec 20, 4:00 PM EST
After hours
44.78
+0.00
0.00%
1 day
6.39%
5 days
6.67%
1 month
60.73%
3 months
376.89%
6 months
439.52%
Year to date
155.89%
1 year
152.28%
5 years
292.46%
10 years
188.90%
 

About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Employees: 150

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.29% more ownership

Funds ownership: 106.78% [Q2] → 108.07% (+1.29%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 54

2% less capital invested

Capital invested by funds: $709M [Q2] → $693M (-$16M) [Q3]

3% less funds holding

Funds holding: 164 [Q2] → 159 (-5) [Q3]

17% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 30

27% less call options, than puts

Call options by funds: $4.71M | Put options by funds: $6.43M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$31
31%
downside
Avg. target
$42
6%
downside
High target
$50
12%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
29% 1-year accuracy
13 / 45 met price target
12%upside
$50
Buy
Maintained
26 Nov 2024
Wedbush
David Nierengarten
38% 1-year accuracy
49 / 128 met price target
5%upside
$47
Outperform
Maintained
25 Nov 2024
Truist Securities
Srikripa Devarakonda
33% 1-year accuracy
10 / 30 met price target
0%upside
$45
Buy
Maintained
25 Nov 2024
Piper Sandler
Allison Bratzel
82% 1-year accuracy
9 / 11 met price target
6%downside
$42
Overweight
Maintained
15 Oct 2024
JP Morgan
Tessa Romero
22% 1-year accuracy
4 / 18 met price target
31%downside
$31
Overweight
Maintained
14 Oct 2024

Financial journalist opinion

Neutral
Business Wire
1 week ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Benzinga
3 weeks ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Neutral
Business Wire
1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to pu.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
1 month ago
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode.
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2024. “We were thrilled to announce positive and statistically significant topline data from the pivotal Phase 3.
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
Neutral
Business Wire
1 month ago
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin antibody, to increase lean mass and lower fat mass gain when taken with metformin. Th.
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
Neutral
Business Wire
1 month ago
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conf.
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Neutral
Business Wire
1 month ago
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma Symposium: Scholar Rock is scheduled to participate in a panel presentation at 3:25 p.
Scholar Rock to Participate in Upcoming Investor Conferences
Neutral
Business Wire
1 month ago
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for I.
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Negative
Benzinga
1 month ago
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of Oct. 25, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Charts implemented using Lightweight Charts™